Literature DB >> 20332768

Dystrophin isoform induction in vivo by antisense-mediated alternative splicing.

Sue Fletcher1, Abbie M Adams, Russell D Johnsen, Kane Greer, Hong M Moulton, Steve D Wilton.   

Abstract

Antisense oligomer-induced manipulation of dystrophin pre-mRNA processing can remove exons carrying mutations, or exclude exons flanking frameshifting mutations, and restore dystrophin expression in dystrophinopathy models and in Duchenne muscular dystrophy (DMD) patients. Splice intervention can also be used to manipulate the normal dystrophin pre-mRNA processing and ablate dystrophin expression in wild-type mice, with signs of pathology being induced in selected muscles within 4 weeks of commencing treatment. The disruption of normal dystrophin pre-mRNA processing to alter the reading frame can be very efficient and offers an alternative mechanism to RNA silencing for gene suppression. In addition, it is possible to remove in-frame exon blocks from the DMD gene transcript and induce specific dystrophin isoforms that retain partial functionality, without having to generate transgenic animal models. Specific exon removal to yield in-frame dystrophin transcripts will facilitate mapping of functional protein domains, based upon exon boundaries, and will be particularly relevant where there is either limited, or conflicting information as to the consequences of in-frame dystrophin exon deletions on the clinical severity and progression of the dystrophinopathy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20332768      PMCID: PMC2889736          DOI: 10.1038/mt.2010.45

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  46 in total

Review 1.  Morpholino oligos: making sense of antisense?

Authors:  Janet Heasman
Journal:  Dev Biol       Date:  2002-03-15       Impact factor: 3.582

2.  Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons.

Authors:  Annemieke Aartsma-Rus; Wendy E Kaman; Rudie Weij; Johan T den Dunnen; Gert-Jan B van Ommen; Judith C T van Deutekom
Journal:  Mol Ther       Date:  2006-06-06       Impact factor: 11.454

Review 3.  Modification of pre-mRNA processing: application to dystrophin expression.

Authors:  Steve D Wilton; Susan Fletcher
Journal:  Curr Opin Mol Ther       Date:  2006-04

4.  Collaborating to bring new therapies to the patient--the TREAT-NMD model.

Authors:  K Bushby; S Lynn; T Straub
Journal:  Acta Myol       Date:  2009-07

5.  Induced dystrophin exon skipping in human muscle explants.

Authors:  G McClorey; A M Fall; H M Moulton; P L Iversen; J E Rasko; M Ryan; S Fletcher; S D Wilton
Journal:  Neuromuscul Disord       Date:  2006-08-21       Impact factor: 4.296

6.  Interactions between dystrophin and the sarcolemma membrane.

Authors:  J S Chamberlain; K Corrado; J A Rafael; G A Cox; M Hauser; C Lumeng
Journal:  Soc Gen Physiol Ser       Date:  1997

7.  Identification of alpha-syntrophin binding to syntrophin triplet, dystrophin, and utrophin.

Authors:  B Yang; D Jung; J A Rafael; J S Chamberlain; K P Campbell
Journal:  J Biol Chem       Date:  1995-03-10       Impact factor: 5.157

Review 8.  Pathophysiology of duchenne muscular dystrophy: current hypotheses.

Authors:  Nicolas Deconinck; Bernard Dan
Journal:  Pediatr Neurol       Date:  2007-01       Impact factor: 3.372

9.  Spectrum of small mutations in the dystrophin coding region.

Authors:  T W Prior; C Bartolo; D K Pearl; A C Papp; P J Snyder; M S Sedra; A H Burghes; J R Mendell
Journal:  Am J Hum Genet       Date:  1995-07       Impact factor: 11.025

10.  Proteomic profiling of antisense-induced exon skipping reveals reversal of pathobiochemical abnormalities in dystrophic mdx diaphragm.

Authors:  Philip Doran; Steve D Wilton; Sue Fletcher; Kay Ohlendieck
Journal:  Proteomics       Date:  2009-02       Impact factor: 3.984

View more
  11 in total

Review 1.  Gene therapies in canine models for Duchenne muscular dystrophy.

Authors:  Peter P Nghiem; Joe N Kornegay
Journal:  Hum Genet       Date:  2019-02-07       Impact factor: 4.132

Review 2.  Correction of muscular dystrophies by CRISPR gene editing.

Authors:  Francesco Chemello; Rhonda Bassel-Duby; Eric N Olson
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

Review 3.  Current status of pharmaceutical and genetic therapeutic approaches to treat DMD.

Authors:  Christophe Pichavant; Annemieke Aartsma-Rus; Paula R Clemens; Kay E Davies; George Dickson; Shin'ichi Takeda; Steve D Wilton; Jon A Wolff; Christine I Wooddell; Xiao Xiao; Jacques P Tremblay
Journal:  Mol Ther       Date:  2011-04-05       Impact factor: 11.454

Review 4.  Development of Therapeutic RNA Manipulation for Muscular Dystrophy.

Authors:  Norio Motohashi; Toshifumi Tsukahara; Yoshitsugu Aoki
Journal:  Front Genome Ed       Date:  2022-05-10

5.  Correcting the NLRP3 inflammasome deficiency in macrophages from autoimmune NZB mice with exon skipping antisense oligonucleotides.

Authors:  Sara J Thygesen; David P Sester; Simon O Cridland; Steve D Wilton; Katryn J Stacey
Journal:  Immunol Cell Biol       Date:  2016-02-02       Impact factor: 5.126

6.  Multiple exon skipping strategies to by-pass dystrophin mutations.

Authors:  Carl F Adkin; Penelope L Meloni; Susan Fletcher; Abbie M Adams; Francesco Muntoni; Brenda Wong; Steve D Wilton
Journal:  Neuromuscul Disord       Date:  2011-12-17       Impact factor: 4.296

7.  The FSHD atrophic myotube phenotype is caused by DUX4 expression.

Authors:  Céline Vanderplanck; Eugénie Ansseau; Sébastien Charron; Nadia Stricwant; Alexandra Tassin; Dalila Laoudj-Chenivesse; Steve D Wilton; Frédérique Coppée; Alexandra Belayew
Journal:  PLoS One       Date:  2011-10-28       Impact factor: 3.240

8.  Antisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD).

Authors:  Eugénie Ansseau; Céline Vanderplanck; Armelle Wauters; Scott Q Harper; Frédérique Coppée; Alexandra Belayew
Journal:  Genes (Basel)       Date:  2017-03-03       Impact factor: 4.096

Review 9.  Cell-Penetrating Peptides to Enhance Delivery of Oligonucleotide-Based Therapeutics.

Authors:  Graham McClorey; Subhashis Banerjee
Journal:  Biomedicines       Date:  2018-05-05

10.  TSUNAMI: an antisense method to phenocopy splicing-associated diseases in animals.

Authors:  Kentaro Sahashi; Yimin Hua; Karen K Y Ling; Gene Hung; Frank Rigo; Guy Horev; Masahisa Katsuno; Gen Sobue; Chien-Ping Ko; C Frank Bennett; Adrian R Krainer
Journal:  Genes Dev       Date:  2012-08-15       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.